Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

PRAX-944 · NP-169944

Small molecule · developed by Praxis Precision Medicines

Phase 2 Most advanced trial (none active)
PRAX Developer
1 Registered trials

What is PRAX-944?

PRAX-944 (also known as NP-169944) is a drug studied in essential tremor, a neurological movement disorder.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NP-169944
Drug type
Small molecule
Therapy area
Neurology
Developer
Praxis Precision Medicines (PRAX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
QT2PJH89C3

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05021991 Phase 2 Essential Tremor Completed PRAX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Essential Tremor

More from Praxis Precision Medicines

Follow PRAX, the company behind PRAX-944

See PRAX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PRAX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.